COMP <GO>
AXGN vs TMDX // RSI-14 & 200D SMA MOMENTUM
Axogen Inc. (NASDAQ) VS. TransMedics Group Inc. (NASDAQ) • 15-METRIC TALLY: AXGN 4
— TMDX 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: AXGN
LAST: $49.63 (+0.77%) • MKT CAP: $2.96B
rsi-technicals
74.3
LAST: $67.12 (+0.33%) • MKT CAP: $2.33B
rsi-technicals
28.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXGN VS. TMDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXGN | TMDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 59.90% | +14.40 | AXGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.60% | 18.10% | -20.70 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 14.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.10% | 5.74% | -5.84 | TMDX | /fcf-yield <GO> |
| Operating Margin | -3.50% | 17.90% | -21.40 | TMDX | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 31.40% | -38.40 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 37.10% | -16.90 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.64 | 3.50 | +15.14 | AXGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 74.3 | 28.9 | +45.37 | AXGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 10.2x | +7.80 | TMDX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.96B | $2.33B | $637.0M | AXGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXGN REV | TMDX REV | AXGN GROSS % | TMDX GROSS % | AXGN FCF | TMDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $225.2M | $605.5M | 74.3% | 59.9% | -$2.9M | $133.6M |
| FY 2024 | $187.3M | $441.5M | 75.8% | 59.4% | $1.4M | -$80.9M |
| FY 2023 | $159.0M | $241.6M | — | — | -$12.9M | -$13.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXGN // BETA 1.10
TMDX // BETA —